GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Risk Assessment

Instituto Rosenbusch (BUE:ROSE) Risk Assessment


View and export this data going back to . Start your Free Trial

What is Instituto Rosenbusch Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Instituto Rosenbusch is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Instituto Rosenbusch's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instituto Rosenbusch's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Risk Assessment falls into.


Instituto Rosenbusch  (BUE:ROSE) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Instituto Rosenbusch Risk Assessment Related Terms

Thank you for viewing the detailed overview of Instituto Rosenbusch's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Instituto Rosenbusch (BUE:ROSE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instituto Rosenbusch SA (BUE:ROSE) » Definitions » Risk Assessment
Comparable Companies
BSP:ARXD11 BSP:DMVF3 BSP:SNCI11 BSP:NUTR3 BSP:JOPA3 BSP:HUCG11 BSP:DTCY3 BSP:FATN11 BSP:DVFF11 BSP:BMIN3 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Website
https://www.rosenbusch.com
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.